We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma Reacts with Concern to FDA’s New Premarket Safety Analytics Efforts
Pharma Reacts with Concern to FDA’s New Premarket Safety Analytics Efforts
The FDA’s efforts to improve premarket safety analytics and documentation were met with comments from several drugmakers expressing concerns about standardization and harmonization with other data systems.